房莹, 吴东, 常春康 . 癌基因与抑癌基因在伯基特淋巴瘤发生发展中的研究进展[J]. 诊断学理论与实践, 2019 , 18(06) : 630 -633 . DOI: 10.16150/j.1671-2870.2019.06.005
| [1] | Dang CV. MYC on the path to cancer[J]. Cell, 2012, 149(1):22-35. |
| [2] | López C, Kleinheinz K, Aukema SM, et al. Genomic and transcriptomic changes complement each other in the pathogenesis of sporadic Burkitt lymphoma[J]. Nat Commun, 2019, 10(1):1459. |
| [3] | Doose G, Haake A, Bernhart SH, et al. MINCR is a MYC-induced lncRNA able to modulate MYC's transcriptional network in Burkitt lymphoma cells[J]. Proc Natl Acad Sci U S A, 2015, 112(38):E5261-5270. |
| [4] | Poole CJ, Zheng W, Lee H, et al. Targeting the MYC Oncogene in Burkitt Lymphoma through HSP90 inhibition[J]. Cancers, 2018, 10(11):pii448. |
| [5] | Egle A, Harris AW, Bouillet P, et al. Bim is a suppressor of Myc-induced mouse B cell leukemia[J]. Proc Natl Acad Sci U S A, 2004, 101(16):6164-6169. |
| [6] | Frenzel A, Labi V, Chmelewskij W, et al. Suppression of B-cell lymphomagenesis by the BH3-only proteins Bmf and Bad[J]. Blood, 2010, 115(5):995-1005. |
| [7] | Michalak EM, Jansen ES, Happo L, et al. Puma and to a lesser extent Noxa are suppressors of Myc-induced lymphomagenesis[J]. Cell Death Differ, 2009, 16(5):684-696. |
| [8] | Hrckulak D, Kolar M, Strnad H, et al. TCF/LEF transcription factors: An update from the internet resources[J]. Cancers, 2016, 8(7) pii: E70. |
| [9] | Kee BL. E and ID proteins branch out[J]. Nat Rev Immunol, 2009, 9(3):175-184. |
| [10] | Schmitz R, Young RM, Ceribelli M, et al. Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics[J]. Nature, 2012, 490(7418):116-120. |
| [11] | Cato MH, Chintalapati SK, Yau IW, et al. Cyclin D3 is selectively required for proliferative expansion of germinal center B cells[J]. Mol Cell Biol, 2011, 31(1):127-137. |
| [12] | Peled JU, Yu JJ, Venkatesh J, et al. Requirement for cyclin D3 in germinal center formation and function[J]. Cell Res, 2010, 20(6):631-646. |
| [13] | Schmitz R, Ceribelli M, Pittaluga S, et al. Oncogenic mechanisms in Burkitt lymphoma[J]. Cold Spring Harb Perspect Med, 2014, 4(2)pii: a014282. |
| [14] | Diehl JA, Cheng M, Roussel MF, et al. Glycogen synthase kinase-3beta regulates cyclin D1 proteolysis and subcellular localization[J]. Genes Dev, 1998, 12(22):3499-3511. |
| [15] | Preudhomme C, Dervite I, Wattel E, et al. Clinical significance of p53 mutations in newly diagnosed Burkitt's lymphoma and acute lymphoblastic leukemia: a report of 48 cases[J]. J Clin Oncol, 1995, 13(4):812-820. |
| [16] | Hüllein J, Slabicki M, Rosolowski M, et al. MDM4 is targeted by 1q gain and drives disease in Burkitt lymphoma[J]. Cancer Res, 2019, 79(12):3125-3138. |
| [17] | Farhat M, Poissonnier A, Hamze A, et al. Reversion of apoptotic resistance of TP53-mutated Burkitt lymphoma B-cells to spindle poisons by exogenous activation of JNK and p38 MAP kinases[J]. Cell Death Dis, 2014, 5:e1201. |
| [18] | Lee JH, Park SJ, Hariharasudhan G, et al. ID3 regulates the MDC1-mediated DNA damage response in order to maintain genome stability[J]. Nat Commun, 2017, 8(1):903. |
| [19] | Love C, Sun Z, Jima D, et al. The genetic landscape of mutations in Burkitt lymphoma[J]. Nat Genet, 2012, 44(12):1321-1325. |
| [20] | Helming KC, Wang X, Wilson BG, et al. ARID1B is a specific vulnerability in ARID1A-mutant cancers[J]. Nat Med, 2014, 20(3):251-254. |
| [21] | Shen J, Peng Y, Wei L, et al. ARID1A deficiency impairs the DNA damage checkpoint and sensitizes cells to PARP Inhibitors[J]. Cancer Discov, 2015, 5(7):752-767. |
/
| 〈 |
|
〉 |
